Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922962 | 0.95 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL923507 | 0.92 | CNR2 (0.54) | CNR2CNR1CYP1A2CYP2C9 | |
| SCHEMBL922846 | 0.90 | CNR2 (0.59) | CNR2CNR1CYP1A2CYP2C9 | |
| SCHEMBL923051 | 0.90 | CNR2 (0.55) | CNR2CNR1CYP1A2CYP2C9 | |
| SCHEMBL924322 | 0.89 | CNR2 (0.58) | CNR2CNR1CYP1A2CYP2C9 | |
| SCHEMBL924634 | 0.88 | CNR2 (0.58) | CNR2 | |
| SCHEMBL922963 | 0.87 | CNR2 (0.57) | CNR2 | |
| SCHEMBL922898 | 0.87 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL924686 | 0.87 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL925312 | 0.87 | CNR2 (0.56) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | claimed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| EP-2097410-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Green Cross Corporation (KR) | 2009-09-09 | — | — | EP | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CNR2 1/4885CNR1 2/4885CYP1A2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.